Registered number
14276048
MHS PHARMS LTD
Filleted Accounts
31 March 2025
MHS PHARMS LTD
Registered number: 14276048
Balance Sheet
as at 31 March 2025
Notes 2025 2024
£ £
Fixed assets
Tangible assets 3 3,886 3,169
Current assets
Debtors 4 19,945 7,429
Cash at bank and in hand 21,611 17,986
41,556 25,415
Creditors: amounts falling due within one year 5 (21,566) (17,541)
Net current assets 19,990 7,874
Total assets less current liabilities 23,876 11,043
Creditors: amounts falling due after more than one year 6 (10,099) (2,491)
Net assets 13,777 8,552
Capital and reserves
Called up share capital 100 100
Profit and loss account 13,677 8,452
Shareholder's funds 13,777 8,552
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The member has not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
MOHAMMAD HAMZA SADIQ
Director
Approved by the board on 9 August 2025
MHS PHARMS LTD
Notes to the Accounts
for the year ended 31 March 2025
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Plant and machinery over 10 years
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
2 Employees 2025 2024
Number Number
Average number of persons employed by the company 3 2
3 Tangible fixed assets
Plant and machinery
£
Cost
At 1 April 2024 3,633
Additions 1,200
At 31 March 2025 4,833
Depreciation
At 1 April 2024 464
Charge for the year 483
At 31 March 2025 947
Net book value
At 31 March 2025 3,886
At 31 March 2024 3,169
4 Debtors 2025 2024
£ £
Trade debtors 19,945 7,429
5 Creditors: amounts falling due within one year 2025 2024
£ £
Corporation Tax 11,488 10,002
Other creditors 10,078 7,539
21,566 17,541
6 Creditors: amounts falling due after one year 2025 2024
£ £
Directors Loan 10,099 2,491
7 Controlling party
The company is under the full control of the director by virtue of them owning 100% of the issued share capital.
8 Other information
MHS PHARMS LTD is a private company limited by shares and incorporated in England. Its registered office is:
110-112 Yews Hill Road
Huddersfield
HD1 3SG
MHS PHARMS LTD 14276048 false 2024-04-01 2025-03-31 2025-03-31 VT Final Accounts July 2024 MOHAMMAD HAMZA SADIQ No description of principal activity 14276048 2023-04-01 2024-03-31 14276048 core:WithinOneYear 2024-03-31 14276048 core:AfterOneYear 2024-03-31 14276048 core:ShareCapital 2024-03-31 14276048 core:RetainedEarningsAccumulatedLosses 2024-03-31 14276048 2024-04-01 2025-03-31 14276048 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 14276048 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 14276048 bus:Director40 2024-04-01 2025-03-31 14276048 1 2024-04-01 2025-03-31 14276048 2 2024-04-01 2025-03-31 14276048 core:PlantMachinery 2024-04-01 2025-03-31 14276048 countries:England 2024-04-01 2025-03-31 14276048 bus:FRS102 2024-04-01 2025-03-31 14276048 bus:FilletedAccounts 2024-04-01 2025-03-31 14276048 2025-03-31 14276048 core:WithinOneYear 2025-03-31 14276048 core:AfterOneYear 2025-03-31 14276048 core:ShareCapital 2025-03-31 14276048 core:RetainedEarningsAccumulatedLosses 2025-03-31 14276048 core:PlantMachinery 2025-03-31 14276048 2024-03-31 14276048 core:PlantMachinery 2024-03-31 iso4217:GBP xbrli:pure